• XPO1 Inhibition and Wnt/β-Catenin in CRC

  2026-08-27

  The reference preprint identifies XPO1 inhibition by Eltanexor (KPT-8602) as a potential chemopreventive strategy in colorectal cancer, linking nuclear export blockade to reduced Wnt/β-catenin activity and COX-2 expression. Its combination of CRC models, Apcmin/+ mice, and tumor-derived organoids provides a mechanistic and preclinical framework for studying cancer therapeutics targeting nuclear export.

• Okadaic acid: PP1/PP2A Workflow Guide

  2026-08-26

  Okadaic acid provides concentration-dependent inhibition of PP2A and PP1 for experiments that link phosphatase activity with phosphorylation, apoptosis, or neuronal signaling readouts. This guide explains practical setup and quality control, while emphasizing that biochemical IC50 values should not be treated as cellular treatment doses or generalized across models.

• ARCA Cy3 EGFP mRNA (5-moUTP) Workflow Guide

  2026-08-26

  Build a quantitative mRNA delivery workflow that tracks both particle uptake and functional EGFP reporter expression in the same experiment. This guide shows how Cy3 labeling, ARCA capping, and 5-methoxyuridine modification can support transfection optimization, localization studies, and endosomal-escape analysis.

• SP2509 Workflow for LSD1-Targeted AML Research

  2026-08-25

  Build reproducible acute myeloid leukemia experiments around SP2509, a selective Lysine-specific demethylase 1 antagonist that connects H3K4 methylation changes with differentiation and apoptosis readouts. The workflow combines solubility control, mechanism-first validation, functional assays, and carefully bounded lessons from combination epigenetics research.

• Quercetin Beyond PI3K: A Translational Playbook

  2026-08-25

  Quercetin is more than a pathway probe: its PI3K, mitochondrial, p53, inflammatory, and ferroptosis-related activities create a translational framework for cancer research and liver injury studies. This article connects mechanistic validation with practical workflow design, while defining the limits of preclinical interpretation.

• miR-18a, ALOXE3, and Ferroptosis in Glioblastoma

  2026-08-24

  Yang and colleagues identify a miR-18a–ALOXE3 regulatory axis that links lipid metabolism to ferroptosis resistance and glioblastoma migration. The study provides a mechanistic framework for interpreting ALOXE3 loss, 12-HETE signaling, and p53-SLC7A11-dependent cell death in preclinical glioblastoma models.

• Cytochalasin D: Actin Uptake Assay Workflows

  2026-08-24

  Use Cytochalasin D as a mechanistic control to distinguish actin-dependent nanoparticle internalization from surface association in corneal epithelial models. This guide also connects the same perturbation logic to cell-cycle, cancer, and viral assays while emphasizing dose control, viability monitoring, and interpretation limits.

• Aurora A Overexpression in Retinoblastoma

  2026-08-23

  A 2024 study identifies Aurora kinase A as frequently overexpressed in human retinoblastoma and links elevated expression with histopathologic high-risk features and poor chemotherapy response. By combining patient-tissue analysis with genetic, pharmacologic, cell-based, and xenograft approaches, the work provides a disease-specific rationale for investigating Aurora A inhibition while stopping short of establishing clinical efficacy.

• LLY-507: A Translational SMYD2 Inhibitor Playbook

  2026-08-22

  LLY-507 offers a selective way to interrogate SMYD2 biology across oncology and cisplatin-associated renal fibrosis models. This thought-leadership guide connects mechanism, assay design, evidence boundaries, and translational strategy for researchers evaluating SMYD2 as a context-dependent target.

• Pifithrin-α: A Translational p53 Test

  2026-08-22

  Pifithrin-α (PFTα) is more than a p53 inhibitor for apoptosis studies. Used as a controlled mechanistic perturbation, it can help translational researchers distinguish p53-dependent apoptosis, ferroptosis, radiation injury, and cell-cycle responses. This article connects product-level evidence with a recent deltamethrin neurotoxicity study and outlines practical validation, formulation, and translational decision points.

• Cytochalasin D for Actin-Dependent Uptake Assays

  2026-08-21

  Cytochalasin D converts actin dynamics into a controllable experimental variable for nanoparticle uptake, cytoskeletal imaging, cell-cycle, and invasion assays. This workflow connects a defined actin perturbation to the 2024 human corneal epithelial cell study while emphasizing dose control, orthogonal readouts, and interpretation limits.

• CX-5461 Drives Mitotic Catastrophe in Cervical Cancer

  2026-08-20

  A June 2026 Biochemical Pharmacology study shows that CX-5461 suppresses cervical cancer cell growth by coupling DNA damage with aberrant mitotic entry and mitotic catastrophe. The findings also indicate that Pol I inhibition can increase cisplatin sensitivity, supporting further investigation in resistant or recurrent disease models.

• Cyclic Pifithrin-α hydrobromide in p53 assays

  2026-08-20

  Cyclic Pifithrin-α hydrobromide provides a reversible chemical approach to dissect p53-dependent transactivation, apoptosis, and DNA-damage responses. This guide translates its established cancer-cell use cases into rigorous assay workflows while clearly separating validated evidence from exploratory applications in neuroinflammation and pain biology.

• GW4064: Non-Steroidal FXR Agonist

  2026-08-19

  GW4064 is a potent, selective non-steroidal FXR agonist for studying bile acid, cholesterol, and triglyceride regulation. Its activity in receptor and cell assays supports FXR activation in metabolic research, while limited aqueous solubility, light sensitivity, and context-specific fibrosis evidence restrict its use to research applications.

• CX-5461: Mapping Ribosome-Stress Responses

  2026-08-19

  CX-5461 is an RNA polymerase I inhibitor that connects rRNA transcriptional stress with DNA damage, mitotic catastrophe, senescence, and autophagy. This article offers a response-state framework for interpreting assays and designing translational cancer research experiments.

8618 records 3/575 page Previous Next 12345 下5页 Last page